Search results

Selected filters:

News

Article type

Topic

Sector

Regions

Year

630 results found for your search

Sort options
18 February 2019

Rolling the dice on eligibility

Congressional action is the only way to solve the uncertainty on section 101 of the US patent statute, argues Aaric Eisenstein of Personalised Media Communications

18 February 2019

Patent deals show how Indian startups can benefit from multinational research activity

An AI health-tech startup recently named one of the world's most promising had its roots in the re-organisation of Xerox's research centre in India

17 February 2019

Giant NPE sold; the US’s first clean hands patent thicketing challenge; inside AT&T’s portfolio; why Huawei owns the future; and much more

Your essential Sunday reading: a summary of all the stories posted on the IAM platform in the past week - as well as links to each one

14 February 2019

The five key takeaways from the USPTO’s report on women and patents

Although female patentees are becoming more common – particularly in areas such as pharma and biotech – the rate of growth is slowing, suggesting that a lot more work needs to be done before equality between the sexes is achieved

13 February 2019

IPBC Global 2019 is shaping up to be the biggest and best of the series so far

Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco 

11 February 2019

Huawei owns the future and that’s why it’s here to stay

Deep pockets, a strong commitment to R&D and a world class 5G patent portfolio mean that whatever its current difficulties the Chinese telecoms business is set to be a major player for the long term

10 February 2019

IBM set to join LOTNet; CAFC decision good news for pharma; TiVo could split; the US’s first biosimilar’s case; and plenty more

Your essential Sunday reading: a summary of all the stories posted on the IAM platform in the past week - as well as links to each one

09 February 2019

The big life sciences patent developments in January

Record-breaking Celgene purchase, two decisions on the on-sale bar, Europe moves towards SPC manufacturing waiver, China proposes five-year patent term extension and much more

06 February 2019

Help to find the IP Hall of Fame inductees for 2019

The annual search for outstanding individuals to induct into the IP Hall of Fame starts today and we want your help.

05 February 2019

USPTO rules on patent term adjustment set to change following CAFC decision

The Federal Circuit’s precedential judgment in Supernus Pharmaceuticals v Iancu is good news for rights holders – especially those in life sciences

04 February 2019

New names added to <em>IAM</em>'s list of Asia-Pac's market-leading IP operations

The Asia IP Elite identifies companies and institutions in the region that have world class IP functions. Here we introduce the 18  latest additions and explain why they have made the cut

03 February 2019

Top IP law and attorney firms announced; no Chinese anti-trust probe of Ericsson – yet; Facebook seals patent deal with IV; Microsoft’s portfolio swings to AI and the cloud; plus much more

Your essential Sunday reading: a summary of all the stories posted on the IAM platform in the past week - as well as links to each one

01 February 2019

We have not been informed of any Chinese antitrust investigation of us, Ericsson tells <em>IAM</em>

Swedish company issues statement after an unsourced Chinese media article claims that a probe into its licensing practices is underway

01 February 2019

Getting to the heart of the life sciences patent debate

SPC disputes, second medical use issues, pharma UPC strategies, CRISPR and much more from IAM’s third annual  pharma and biotech IP conference, which took place in London earlier this week

31 January 2019

Pressure piles on US pharma and biotech IP owners

America's life sciences innovators face accusations of using patents to build monopolies and overcharge for vital medicines. If they do not tell their side of the story and fast, they risk losing vital protections on which they rely